Ultragenyx Pharmaceutical Stock (NASDAQ: RARE) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 699.509K |
Day Range | - - - |
52 Wk Range | 31.520 - 54.980 |
Market Cap | $3.703B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 46 |
Short Interest | 4.95% |
Days to Cover | 7.08 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Ultragenyx Pharmaceutical (NASDAQ: RARE) through any online brokerage.
Other companies in Ultragenyx Pharmaceutical’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Alkermes (NASDAQ:ALKS), SpringWorks Therapeutics (NASDAQ:SWTX) and Arrowhead Pharma (NASDAQ:ARWR).
The latest price target for Ultragenyx Pharmaceutical (NASDAQ: RARE) was reported by TD Cowen on Wednesday, April 24, 2024. The analyst firm set a price target for 61.00 expecting RARE to rise to within 12 months (a possible 35.62% upside). 28 analyst firms have reported ratings in the last year.
The stock price for Ultragenyx Pharmaceutical (NASDAQ: RARE) is $44.98 last updated April 24, 2024 at 4:36 PM EDT.
There are no upcoming dividends for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.